Dr. Mathew Garnett presents his research on synthetic-lethal drug target discovery at the 2019 AACR-EORTC-NCI Meeting on Molecular Targets and Cancer Therapeutics

The international symposium discusses the latest innovations in drug development and target selection. Mathew presented his use of unbiased genome-scale CRISPR genetic screens to identify and prioritise oncology targets. His work led to the discovery of Werner helicase as a synthetic-lethal target in a defined set of patients with genetic alterations leading to defects in DNA mismatch repair.  Dr. Mathew Garnett is Co-founder and Chief Scientific Officer of Mosaic Therapeutics.


About MOSAIC

We are a cancer therapeutics company using advanced computational methods and next-generation cancer models to find new synthetic-lethal cancer targets. Our main mission is to tackle cancers with substantial unmet need by reinventing target discovery. We have active programmes across a variety of cancer indications and disease biology fields and we are seeking strategic alliances with pharma companies who wish to leverage our world-leading data and platforms.

Born out of pioneering research at the Wellcome Sanger Institute and anchored around a proprietary database that has seen 20 years of tuning and development, our tools and know-how will provide our partners with an unparalleled complement of world-leading capabilities.

For media and editorial enquiries, please email: contact@mosaic-tx.com